The Objectives of the FDA's Office of Generic Drugs
Year of publication: |
August 1997
|
---|---|
Authors: | Morton, Fiona Scott |
Institutions: | National Bureau of Economic Research (contributor) |
Publisher: |
Cambridge, Mass : National Bureau of Economic Research |
Subject: | Generika | Generic drugs | Arzneimittel | Pharmaceuticals | Pharmaindustrie | Pharmaceutical industry | Arzneimittelrecht | Pharmaceutical law | Arzneimittelmarkt | Pharmaceutical market |
Extent: | 1 Online-Ressource |
---|---|
Series: | NBER working paper series ; no. w6143 |
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Mode of access: World Wide Web System requirements: Adobe [Acrobat] Reader required for PDF files Hardcopy version available to institutional subscribers. |
Other identifiers: | 10.3386/w6143 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
The Objectives of the Fda's Office of Generic Drugs
Scott Morton, Fiona M., (2022)
-
Empirical evidence of risk penalties for NTI Drugs
Gentry, Elissa Philip, (2019)
-
The effect of inertia on brand-name versus generic drug choices
Ito, Yuki, (2020)
- More ...
-
The Strategic Positioning of Store Brands in Retailer - Manufacturer Bargaining
Morton, Fiona Scott, (2000)
-
Antitrust and Innovation : Welcoming and Protecting Disruption
Federico, Giulio, (2019)
-
Do Increasing Markups Matter? Lessons from Empirical Industrial Organization
Berry, Steven T., (2019)
- More ...